Radiolabeled tracers for imaging of tumor angiogenesis and evaluation of anti-angiogenic therapies.
about
Noninvasive visualization of the activated alphavbeta3 integrin in cancer patients by positron emission tomography and [18F]Galacto-RGDAn in vivo evaluation of the effect of repeated administration and clearance of targeted contrast agents on molecular imaging signal enhancementSynergistic effects of light-emitting probes and peptides for targeting and monitoring integrin expression.Phage display in molecular imaging and diagnosis of cancer.Evaluation of 111In-labeled cyclic RGD peptides: tetrameric not tetravalent2-Mercaptoacetylglycylglycyl (MAG2) as a bifunctional chelator for 99mTc-labeling of cyclic RGD dimers: effect of technetium chelate on tumor uptake and pharmacokineticsImaging chemically modified adenovirus for targeting tumors expressing integrin alphavbeta3 in living mice with mutant herpes simplex virus type 1 thymidine kinase PET reporter gene.Quantitative PET imaging of tumor integrin alphavbeta3 expression with 18F-FRGD2.Impact of multiple negative charges on blood clearance and biodistribution characteristics of 99mTc-labeled dimeric cyclic RGD peptidesComparison of 99mTc-3PRGD2 integrin receptor imaging with 99mTc-MDP bone scan in diagnosis of bone metastasis in patients with lung cancer: a multicenter study.Evaluation of ανβ3-mediated tumor expression with a 99mTc-labeled ornithine-modified RGD derivative during glioblastoma growth in vivoRadiolabeled Cyclic RGD Peptides as Radiotracers for Imaging Tumors and Thrombosis by SPECTPilot pharmacokinetic and dosimetric studies of (18)F-FPPRGD2: a PET radiopharmaceutical agent for imaging α(v)β(3) integrin levelsStudy on the expression and clinical significances of lewis y antigen and integrin αv, β3 in epithelial ovarian tumors.Near-infrared fluorescence imaging of tumor integrin alpha v beta 3 expression with Cy7-labeled RGD multimersEvaluation of In-Labeled Cyclic RGD Peptides: Effects of Peptide and Linker Multiplicity on Their Tumor Uptake, Excretion Kinetics and Metabolic Stability.Endothelial targeting of polymeric nanoparticles stably labeled with the PET imaging radioisotope iodine-124.Imaging angiogenesis: applications and potential for drug development.Coligand effects on the solution stability, biodistribution and metabolism of the (99m)Tc-labeled cyclic RGDfK tetramerStable isotope- and mass spectrometry-based metabolomics as tools in drug metabolism: a study expanding tempol pharmacology.Design of targeted cardiovascular molecular imaging probes.Biodistribution and fate of core-labeled 125I polymeric nanocarriers prepared by Flash NanoPrecipitation (FNP).Linker effects on biological properties of 111In-labeled DTPA conjugates of a cyclic RGDfK dimerImpact of PKM linkers on biodistribution characteristics of the 99mTc-labeled cyclic RGDfK dimerFirst experience of 18F-alfatide in lung cancer patients using a new lyophilized kit for rapid radiofluorinationImproving tumor uptake and excretion kinetics of 99mTc-labeled cyclic arginine-glycine-aspartic (RGD) dimers with triglycine linkersImproving tumor-targeting capability and pharmacokinetics of (99m)Tc-labeled cyclic RGD dimers with PEG(4) linkers.The functions and applications of RGD in tumor therapy and tissue engineering.Improving tumor uptake and pharmacokinetics of (64)Cu-labeled cyclic RGD peptide dimers with Gly(3) and PEG(4) linkersThe Use of Phage-Displayed Peptide Libraries to Develop Tumor-Targeting Drugs.(64)Cu-labeled CB-TE2A and diamsar-conjugated RGD peptide analogs for targeting angiogenesis: comparison of their biological activityIntegrin α(v)β₃-targeted radiotracer (99m)Tc-3P-RGD₂ useful for noninvasive monitoring of breast tumor response to antiangiogenic linifanib therapy but not anti-integrin α(v)β₃ RGD₂ therapy.Radiolabeled cyclic RGD peptides as integrin alpha(v)beta(3)-targeted radiotracers: maximizing binding affinity via bivalency.Integrin-targeted molecular imaging of experimental abdominal aortic aneurysms by (18)F-labeled Arg-Gly-Asp positron-emission tomography.(99m)Tc-Galacto-RGD2: a novel 99mTc-labeled cyclic RGD peptide dimer useful for tumor imaging.Efficient preparation and biological evaluation of a novel multivalency bifunctional chelator for 64Cu radiopharmaceuticalsEffects of integrins and integrin αvβ3 inhibitor on angiogenesis in cerebral ischemic stroke.MicroPET imaging of tumor angiogenesis and monitoring on antiangiogenic therapy with an (18)F labeled RGD-based probe in SKOV-3 xenograft-bearing mice.Imparting multivalency to a bifunctional chelator: a scaffold design for targeted PET imaging probes.In vivo and in vitro characterisation of a protoporphyrin IX-cyclic RGD peptide conjugate for use in photodynamic therapy.
P2860
Q24805375-2680EF58-8FD8-420A-BBFE-13E779E18839Q30458183-71C3AB65-8F48-410F-A718-1857C1E4CE83Q33215681-D2831FAA-4A2B-43FB-9ABC-6F8924CF7976Q33532734-5DB84760-2E69-4544-852F-C14EEE5844D7Q33867187-8BBC0D9D-92A3-4BF3-8B57-3B87109CEA65Q33925952-8F25A3F6-F1C3-45C2-BA82-C5D0E41C72BAQ34134316-0A1C5676-F612-45C9-8AF7-9AE7E88677ABQ34159304-7FE9DD16-A5F8-47CA-BB4F-BCB39746B62BQ34196969-760171C5-5FEE-4FF6-BFC5-8A4764982C2AQ34388500-8C1C3AD6-F220-42D2-A490-D87BB1F355CCQ34712744-17621FD0-D61F-4B78-A72A-109B85B48AB9Q34912643-B0A78F73-F700-41A9-8800-491C38E19C5EQ35062113-C54BFFFD-9F9B-4A81-BFDD-E431021390A0Q35091734-D33B665D-A54B-43F7-9073-D9B9444E2F4CQ35141638-7DAF5B62-12B4-46BA-AAEE-94BB299000AEQ35167459-C365477D-97CB-41A8-8002-54A4F68D5453Q35973379-20B24E5D-828F-4812-8C6C-CEBE6F42BEF7Q36027611-CA55773F-53F8-4F24-BF0E-5DE1B055DA6EQ36515561-89AAF48D-946B-4F0B-B753-974AE82E1756Q36676188-10B36E8B-C410-4CDE-8B1C-ED70CD06442CQ36777401-AE5A6441-AB19-425A-B7CE-2B46E1957196Q36783691-8AF22B65-7581-43D3-BADE-DA29EFD7FBA5Q36865548-ACDBBE2E-080E-47FC-ADE4-7089EC9A7DA6Q36924767-189C5E8B-5C7C-48CE-8376-9157F5052BE0Q36931413-F8E24CA7-72B2-4C59-A3F9-EE8400629054Q37060623-1730F607-B8CD-441F-B1D5-1575837513AAQ37081396-A48D5164-5303-45D9-BE5A-AF5F7F12C97BQ37091818-2C0C9366-3F03-4470-BB20-3EA57C4FE505Q37178786-6DD4845E-3445-48E8-B96A-8153819127EBQ37183977-7C813F29-F920-433C-82D1-310914DF0233Q37218456-E76E7B6F-0E42-41EE-83FF-408E5F0F8ECDQ37344824-FFAD5730-6C33-4C14-8F7D-89208D99CA8BQ37480688-79B55A5C-A576-4414-9F20-D7B488DA41C9Q37540738-DA71AE9E-A79E-497E-A5BE-D64318459943Q37624526-D463F2C9-8458-4A02-B739-935B7563E4E6Q37722948-4390B170-718B-4D30-8793-A00E70DAE72CQ38221073-29C8AA50-3809-417C-9723-534681A1C8D8Q38929240-C13C1566-496E-4A95-AD3C-EF8BD6B46987Q39804673-9EC19E2E-411D-47AA-81C7-1EFFF9FACAB3Q39994999-80A67CB9-9E16-481C-AE23-B1865EF55140
P2860
Radiolabeled tracers for imaging of tumor angiogenesis and evaluation of anti-angiogenic therapies.
description
2004 nî lūn-bûn
@nan
2004 թուականի Յունուարին հրատարակուած գիտական յօդուած
@hyw
2004 թվականի հունվարին հրատարակված գիտական հոդված
@hy
2004年の論文
@ja
2004年論文
@yue
2004年論文
@zh-hant
2004年論文
@zh-hk
2004年論文
@zh-mo
2004年論文
@zh-tw
2004年论文
@wuu
name
Radiolabeled tracers for imagi ...... of anti-angiogenic therapies.
@ast
Radiolabeled tracers for imagi ...... of anti-angiogenic therapies.
@en
type
label
Radiolabeled tracers for imagi ...... of anti-angiogenic therapies.
@ast
Radiolabeled tracers for imagi ...... of anti-angiogenic therapies.
@en
prefLabel
Radiolabeled tracers for imagi ...... of anti-angiogenic therapies.
@ast
Radiolabeled tracers for imagi ...... of anti-angiogenic therapies.
@en
P356
P1476
Radiolabeled tracers for imagi ...... of anti-angiogenic therapies.
@en
P2093
Hans-Jürgen Wester
Roland Haubner
P304
P356
10.2174/1381612043384745
P577
2004-01-01T00:00:00Z